Physician

Jane Barbosa Ayala, M.D.

According to 2025 Medicare claims, Jane Ayala, M.D. (NPI: 1093914681) practices rheumatology in the San Antonio-New Braunfels, TX market, with the plurality of this provider's patient population coming from Bexar, TX. This provider's primary affiliated billing organization is RHEUMATOLOGY ASSOCIATES OF SOUTH TEXAS, PLLC (NPI: 1952351538; TIN: 161751617) and primary practice location at 78251-4417. Ayala is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Ayala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 430 traditional Medicare patients, billed 152,662 HCPCS/CPT codes, and received $2,087,224 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,126 prescription claims across 404 beneficiaries totaling $2,165,902 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 135 records totaling $2,647. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $561,868 to $2,087,224. Concurrently, Part D prescription costs have changed little. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	316	45,902	$561,868
2016	363	57,176	$868,414
2017	338	94,861	$1,340,302
2018	347	96,668	$1,703,717
2019	320	109,606	$1,826,281
2020	349	151,016	$2,641,856
2021	364	174,616	$3,058,940
2022	438	151,233	$2,180,068
2023	425	128,947	$1,776,577
2024	430	152,662	$2,087,224

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	336	5,415	$2,793,108
2016	374	6,469	$2,948,585
2017	379	4,462	$2,679,917
2018	373	3,451	$2,639,644
2019	355	2,789	$2,505,985
2020	401	2,972	$2,731,914
2021	389	2,598	$2,416,892
2022	377	2,321	$2,373,736
2023	360	2,228	$2,756,850
2024	404	2,126	$2,165,902

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	359	960	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	353	836	$12
80053	Blood test, comprehensive group of blood chemicals	313	850	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	309	820	$8
86140	Measurement c-reactive protein for detection of infection or inflammation	312	834	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	46	2,016	$473,568
Enbrel Sureclick	Etanercept	52	1,456	$406,316
Orencia Clickject	Abatacept	41	1,544	$317,554
Cosentyx Sensoready Pen	Secukinumab	15	588	$146,914
Cosentyx Sensoready (2 Pens)	Secukinumab	11	728	$138,906

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	135	$2,647	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jane Barbosa Ayala, M.D.?

Tedicare shows public-source Medicare data for Jane Barbosa Ayala, M.D. (NPI 1093914681), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jane Barbosa Ayala, M.D. have ACO affiliation data?

Jane Barbosa Ayala, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Jane Barbosa Ayala, M.D.?

Jane Barbosa Ayala, M.D. is linked to RHEUMATOLOGY ASSOCIATES OF SOUTH TEXAS, PLLC (billing NPI 1952351538) in the available physician profile data.

Does Jane Barbosa Ayala, M.D. have Open Payments data?

Jane Barbosa Ayala, M.D. has 135 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.